Sunday , August 7 2022

the derogation of the drugs had adverse consequences, according to society


The Alzheimer's French association identifies the results for patients with anti-Alzheimer's drugs being paid, seven months after they come into force.

Exacerbate symptoms after stopping treatment, increasing spending: the fact that anti-Alzheimer's drugs, considered ineffective, have had harmful consequences for patients, said Thursday, February 21, Society Alzheimer's France, almost seven months after its power into force. Four drugs (Aricept, Ebixa, Exelon and Reminyl) are no longer repayable since August 1, while they were earlier up to 15%.

"Families are poor and this dangerous decision has only increased their financial, psychological and medical distress"denotes society in a statement.

Health Minister Agnès Buzyn had made the reimbursement decision based on an evaluation by the High Health Authority (HAS), who had judged that all of these drugs had been received "insufficient medical interest to justify their care". She also pointed out "the existence of potentially serious adverse effects".

An animal challenged by the societies. "Carers as sick people testify to the effectiveness of these drugs and the catastrophic effect of a breach of treatment"says Alzheimer's France, which is based on consultation with more than 2,500 people (2,463 carers and 84 patients). The society adds that it will fund "clinical study of up to 200,000 euros", and hope to prove the effectiveness of the treatment.

To read too

Source link